Latest news with #bevacizumab
&w=3840&q=100)
Business Standard
11-08-2025
- Business
- Business Standard
Biocon shares slip 3% as Q1 results miss estimates; should you sell?
Shares of Biocon fell over 3 per cent on Monday after the company reported a 95.2 per cent year-on-year (Y-o-Y) decline in net profit in the first quarter of the current financial year (Q1FY26). The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 this year. The stock pared losses to trade 0.9 per cent higher at ₹340.4 apiece, compared to a 0.22 per cent advance in Nifty 50 as of 11:45 AM. Shares of the company fell for the second straight day and currently trade at 1.5 times the average 30-day trading volume, according to Bloomberg. The counter has fallen 7.2 per cent this year, compared to a 3.3 per cent advance in the benchmark Nifty 50. Biocon has a total market capitalisation of ₹45,349.81 crore. Biocon Q1 results The Bengaluru-based company reported a 95.2 per cent Y-o-Y drop in consolidated net profit at ₹31 crore in Q1FY26, compared to ₹660 crore in the same period last year. The Q1 FY25 profit included a one-time divestment gain, impacting this year's base. The firm's revenue rose 15 per cent to ₹4,022 crore on a like-for-like basis after adjusting for the one-time gain in the base quarter. Operating revenue increased 15 per cent to ₹3,942 crore in Q1 FY26, up from ₹3,433 crore in Q1 FY25. The generics business reported revenue of ₹697 crore, a 6 per cent Y-o-Y increase, while the CRDMO business, Syngene, reported revenue of ₹875 crore, up 11 per cent Y-o-Y. 'Biocon opened FY26 with a strong performance, driven by continued gains in biosimilars and CRDMO, and a steady showing in generics. The recent QIP has strengthened our balance sheet and enabled us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities,' said Kiran Mazumdar-Shaw, chairperson, Biocon Group. Analysts in Biocon earnings Nuvama Institutional Equities said Biocon's Q1FY26 revenue and Ebitda missed consensus estimates by 2 per cent and 11 per cent, respectively, due to weakness in the generics segment. The brokerage noted market share gains in key biosimilar products, steady margins, and upcoming launches of bAspart, denosumab, bevacizumab, and bEylea as positive signs. However, it said execution will be critical to achieving high growth, with the generics segment still dragging and consistent margin delivery yet to be demonstrated amid elevated costs from new facilities. Nuvama maintained its 'Hold' rating on the stock, with a revised target price of ₹365, up from ₹345 earlier. Motilal Oswal said Biocon's Q1FY26 financial performance came in below expectations, primarily due to a sharp decline in generics sales and higher operating expenses. The brokerage noted that Biocon is building growth levers across its generics, biologics, and Syngene businesses, with an encouraging product pipeline in both generics and biologics. It cut its earnings estimates by 7 per cent for FY26 and 3 per cent for FY27, while maintaining a 'Buy' rating with a target price of ₹410.
Globe and Mail
22-07-2025
- Business
- Globe and Mail
Outlook Therapeutics Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, newly appointed Chief Executive Officer, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Jahr dove deeper into what brought him to Outlook Therapeutics, how he got to where he is today and provided insight into why he is excited about the future for Outlook Therapeutics. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Jenene Thomas
Medscape
19-06-2025
- Health
- Medscape
Intensive Bevacizumab Boosts Vision in Macular Degeneration
Dutch patients with neovascular age-related macular degeneration (AMD) who initiated bevacizumab achieved greater long-term improvements in visual acuity than patients in socioeconomically similar countries in which patients started ranibizumab or aflibercept — likely because of early and more intensive treatment in the Netherlands. METHODOLOGY: Researchers evaluated the long-term outcomes of anti-VEGF therapy for neovascular AMD in the Netherlands — where bevacizumab is the mandated first-line drug — to assess if improvements in vision were superior to those in socioeconomically similar countries using ranibizumab or aflibercept. They analyzed 5-year data from the Fight Retinal Blindness! registry, comparing outcomes for 1473 eyes in 1229 patients treated with bevacizumab (Dutch cohort) with those for 7144 eyes in 5884 patients receiving aflibercept or ranibizumab (reference cohort). Patients enrolled in the registry after January 1, 2016, with at least 6 months of follow-up and no prior history of treatment with an anti-VEGF agent were included in the analysis. Primary outcome measures were mean visual acuity at yearly intervals until 60 months, and secondary outcomes included injection frequency and rates of switching to alternative anti-VEGF agents. TAKEAWAY: At 60 months, mean visual acuity among patients in the Dutch cohort was 2.3 letters higher than that of patients in reference cohort; eyes with poor baseline vision in the Dutch cohort showed sustained improvements through month 60, whereas their counterparts in the reference cohort regressed to poor vision within 3 years. Patients in the Dutch cohort received 14.5 more injections over 5 years than those in the reference cohort, indicating a more aggressive treatment approach. At 60 months, the Dutch cohort also showed higher rates of switching to alternative anti-VEGF agents than the reference cohort (70.9% vs 51.9%), with a shorter median time to switching (11.9 vs 17.7 months), suggesting ophthalmologists in the Netherlands were quicker to change therapy when patients exhibited a poor response to treatment. IN PRACTICE: 'There is little evidence to suggest that the higher visual outcomes for the Dutch group are due to the choice of drug as bevacizumab has not been shown to be superior to other anti-VEGF drugs,' the researchers wrote. 'The head-to-head trials against ranibizumab, IVAN and CATT, only demonstrated that bevacizumab was not inferior. The higher visual gain is likely to result from a more aggressive injection frequency' as well as a higher visual acuity at baseline. SOURCE: The study was led by H. Mhmud and J. P. Vermeulen, of the Department of Ophthalmology at Erasmus Medical Center in Rotterdam, the Netherlands. It was published online on June 15, 2025, in Ophthalmology and Therapy . LIMITATIONS: A key limitation noted by the researchers was the lack of information about specific treatment regimens used. Decisions about treatment were made by the individual clinicians, and little is known about the reason behind their choices. Reasons for loss to follow-up were recorded for less than 20% of patients. DISCLOSURES: This study did not receive any funding. The authors declared having no conflicts of interest.
Associated Press
23-05-2025
- Business
- Associated Press
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold in combination with an accompanying warrant to purchase two shares of common stock issued for each share of common stock sold. The accompanying warrant has an exercise price of $1.40 per share, will become exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on May 27, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million. Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes. BTIG, LLC is acting as sole book-running manager for the offering. The securities described above are being offered by Outlook Therapeutics pursuant to a shelf registration statement on Form S-3 (No. 333-278340) that was declared effective by the Securities and Exchange Commission (SEC) on April 5, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at Copies of the preliminary prospectus supplement and the final prospectus supplement relating to this offering may be obtained, when available, by contacting: BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and Medicines and Healthcare products Regulatory Agency Marketing Authorization for the treatment of wet age-related macular degeneration (wet AMD). Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the European Union and the United Kingdom as a treatment for wet AMD, expected in the second quarter of calendar year 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a Biologics License Application has been resubmitted to the U.S. Food and Drug Administration. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements regarding the gross proceeds from the offering, the use of proceeds from the offering, the completion of the offering, expectations concerning decisions of regulatory bodies and the timing thereof, plans for commercial launch of LYTENAVA™ in the EU and the UK and the timing thereof and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include fluctuations in Outlook Therapeutics' stock price, changes in market conditions and satisfaction of customary closing conditions related to the offering, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, and the sufficiency of Outlook Therapeutics' resources, as well as those risks detailed in Outlook Therapeutics' filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, and subsequent filings with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775 [email protected] Source: Outlook Therapeutics, Inc.
